0H8T.L
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in the United States, dedicated to discovering and advancing novel therapeutic agents for immune-inflammatory diseases. The company operates through two distinct divisions: Therapeutics and Contract Research. The Therapeutics segment focuses on identifying and developing cutting-edge treatments to address significant unmet medical needs within the realm of immunological and inflammatory conditions. Complementing this, the Contract Research segment offers specialized laboratory services. Aclaris boasts a robust development pipeline, featuring several key drug candidates. These include Zunsemetinib, an MK2 inhibitor, c...[Read more]
Industry
Biotechnology
IPO Date
2018-01-29
Stock Exchange
LSE
Ticker
0H8T.L
According to Aclaris Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -10.21. This represents a change of 131.49% compared to the average of -4.41 of the last 4 quarters.
The mean historical PE Ratio of Aclaris Therapeutics, Inc. over the last ten years is -5.88. The current -10.21 PE Ratio has changed 17.26% with respect to the historical average. Over the past ten years (40 quarters), 0H8T.L's PE Ratio was at its highest in in the September 2019 quarter at -0.20. The PE Ratio was at its lowest in in the March 2017 quarter at -15.53.
Average
-5.88
Median
-5.54
Minimum
-12.06
Maximum
-0.55
Discovering the peaks and valleys of Aclaris Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 887.05%
Maximum Annual PE Ratio = -0.55
Minimum Annual Increase = -93.02%
Minimum Annual PE Ratio = -12.06
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -5.68 | 291.59% |
| 2024 | -1.45 | 75.42% |
| 2023 | -0.83 | -93.02% |
| 2022 | -11.84 | 30.31% |
| 2021 | -9.09 | 68.55% |
| 2020 | -5.39 | 887.05% |
| 2019 | -0.55 | -70.21% |
| 2018 | -1.83 | -81.86% |
| 2017 | -10.11 | -16.21% |
| 2016 | -12.06 | -50.75% |
The current PE Ratio of Aclaris Therapeutics, Inc. (0H8T.L) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-2.65
5-year avg
-5.78
10-year avg
-5.88
Aclaris Therapeutics, Inc.’s PE Ratio is less than Sangamo Therapeutics, Inc. (0), less than Heron Therapeutics, Inc. (-2.66), less than Corbus Pharmaceuticals Holdings, Inc. (-1.37), less than Accuray Incorporated (-0.70), less than Codexis, Inc. (-6.12), less than Adicet Bio, Inc. (-0.54), less than Editas Medicine, Inc. (-2.43), less than Abeona Therapeutics Inc. (5.45), greater than Atara Biotherapeutics Inc (-12.71), less than Insight Molecular Diagnostics Inc. (-3.13),
| Company | PE Ratio | Market cap |
|---|---|---|
| 0 | N/A | |
| -2.66 | N/A | |
| -1.37 | N/A | |
| -0.70 | N/A | |
| -6.12 | N/A | |
| -0.54 | N/A | |
| -2.43 | N/A | |
| 5.45 | N/A | |
| -12.71 | N/A | |
| -3.13 | N/A |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aclaris Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aclaris Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Aclaris Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Aclaris Therapeutics, Inc. (0H8T.L)?
What is the highest PE Ratio for Aclaris Therapeutics, Inc. (0H8T.L)?
What is the 3-year average PE Ratio for Aclaris Therapeutics, Inc. (0H8T.L)?
What is the 5-year average PE Ratio for Aclaris Therapeutics, Inc. (0H8T.L)?
How does the current PE Ratio for Aclaris Therapeutics, Inc. (0H8T.L) compare to its historical average?